Aeglea Bio Therapeutics Valuation
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
Aeglea Bio is overvalued. Aeglea Bio Therapeutics shows a prevailing Real Value of $0.42 per share. The current price of the firm is $0.59. Our model approximates the value of Aeglea Bio Therapeutics from analyzing the firm fundamentals such as operating margin of (94.85) %, and Return On Equity of -2.81 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Aeglea Bio's price fluctuation is very steady at this time. Calculation of the real value of Aeglea Bio Therapeutics is based on 3 months time horizon. Increasing Aeglea Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Aeglea stock is determined by what a typical buyer is willing to pay for full or partial control of Aeglea Bio Therapeutics. Since Aeglea Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aeglea Stock. However, Aeglea Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.59 | Real 0.42 | Hype 0.59 | Naive 0.55 |
The real value of Aeglea Stock, also known as its intrinsic value, is the underlying worth of Aeglea Bio Therapeutics Company, which is reflected in its stock price. It is based on Aeglea Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Aeglea Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Aeglea Bio Therapeutics helps investors to forecast how Aeglea stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aeglea Bio more accurately as focusing exclusively on Aeglea Bio's fundamentals will not take into account other important factors: Aeglea Bio Total Value Analysis
Aeglea Bio Therapeutics is presently expected to have valuation of 228.21 M with market capitalization of 45.59 M, debt of 4.63 M, and cash on hands of 73.68 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aeglea Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
228.21 M | 45.59 M | 4.63 M | 73.68 M |
Aeglea Bio Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. Based on the analysis of Aeglea Bio's profitability, liquidity, and operating efficiency, Aeglea Bio Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Aeglea Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aeglea Bio has an asset utilization ratio of 3.27 percent. This indicates that the Company is making $0.0327 for each dollar of assets. An increasing asset utilization means that Aeglea Bio Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Aeglea Bio Ownership Allocation
The majority of Aeglea Bio Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aeglea Bio Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aeglea Bio. Please pay attention to any change in the institutional holdings of Aeglea Bio Therapeutics as this could imply that something significant has changed or is about to change at the company.Aeglea Bio Profitability Analysis
The company reported the previous year's revenue of 2.33 M. Net Loss for the year was (83.81 M) with loss before overhead, payroll, taxes, and interest of (262 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Aeglea Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Aeglea Bio and how it compares across the competition.
About Aeglea Bio Valuation
The delisted stock valuation mechanism determines Aeglea Bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of Aeglea Bio. We calculate exposure to Aeglea Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aeglea Bio's related companies.Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Aeglea Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Aeglea Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 3.4 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |